阿斯利康

原文：AstraZeneca｜最近更新：2026-09-05

原文名稱
AstraZeneca
縮寫
AZN
類型
藥廠
國家
英國
主管領域／業務範圍
跨國製藥（腫瘤、心血管腎臟代謝、呼吸免疫、疫苗等）

關鍵人物

—

相關政策

—

相關藥品

Zegfrovy、Etcamah、（尚無商品名）、Enhertu、Orpathys、Tagrisso、Tezspire、Wainua

涉及事件

AstraZeneca以最高15億美元授權取得Dizal Pharmaceutical肺癌新藥Zegfrovy（sunvozertinib）全球權利、AstraZeneca乳癌新藥camizestrant（Etcamah）獲歐盟核准一線適應症，美國FDA後續加速核准同一適應症、AstraZeneca與Bristol Myers Squibb傳出近4000億美元合併早期談判，消息人士後否認、AstraZeneca與石藥集團（CSPC）於中國成立生物製劑原料藥製造合資企業、ICER草稿報告認定AstraZeneca新藥Baxfendy(baxdrostat)未達成本效益門檻、AstraZeneca肺癌管線一日三案：volrustomig第三期試驗終止，Enhertu與Orpathys併Tagrisso雙雙達標、AstraZeneca／Amgen Tezspire（tezepelumab）CROSSING第三期試驗於嗜酸性食道炎達主要終點、AstraZeneca／Ionis之Wainua（eplontersen）ATTR-CM三期CARDIO-TTRansform試驗未達主要終點，ESC年會發表完整數據

關聯關係

關係建立日期強度確定程度證據來源補充說明
達成協議 → AstraZeneca以最高15億美元授權取得Dizal Pharmaceutical肺癌新藥Zegfrovy（sunvozertinib）全球權利2026-07-14強確認AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal PharmaceuticalAstraZeneca授權取得Zegfrovy全球權利
提交申請 → AstraZeneca乳癌新藥camizestrant（Etcamah）獲歐盟核准一線適應症，美國FDA後續加速核准同一適應症2026-07-24強確認Camizestrant recommended for breast cancer in EU (Etcamah approved in the EU for ER+ breast cancer)AstraZeneca之camizestrant（Etcamah）獲歐盟執委會核准一線乳癌適應症；美國FDA審查中。歐盟執委會為核准機關，尚未於kb/orgs建檔，此relation記錄AstraZeneca身為藥品所有廠商與事件之關聯
進行併購 → 必治妥施貴寶2026-08-02弱推論AstraZeneca said to have explored Bristol Myers merger媒體報導雙方近月曾就近4000億美元合併進行早期階段談判，雙方均未證實，關係強度標記為弱、確定程度為推論
參與 → AstraZeneca與Bristol Myers Squibb傳出近4000億美元合併早期談判，消息人士後否認2026-08-02中確認AstraZeneca said to have explored Bristol Myers merger為傳出合併談判之一方
石藥集團 → 達成協議2026-08-05強確認CSPC Pharmaceutical, AstraZeneca Form Joint Venture for New Biologics Manufacturing Facility in China成立生物製劑原料藥製造合資企業，CSPC佔股51%、AstraZeneca佔股49%，為雙方三年內第三次重大戰略協議
參與 → ICER草稿報告認定AstraZeneca新藥Baxfendy(baxdrostat)未達成本效益門檻2026-08-13強確認AZ's blood pressure newcomer Baxfendy fails to meet cost-effectiveness bar, ICER saysBaxfendy原廠，回應ICER報告並強調藥物創新價值
執行 → AstraZeneca肺癌管線一日三案：volrustomig第三期試驗終止，Enhertu與Orpathys併Tagrisso雙雙達標2026-08-18強確認AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failureAstraZeneca為volrustomig、Enhertu、Orpathys併Tagrisso三項試驗之共同主導開發方
第一三共 → 合作2026-08-18強確認AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure第一三共與AstraZeneca共同開發ADC藥物Enhertu
和黃醫藥 → 合作2026-08-18強確認AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failureHUTCHMED與AstraZeneca共同開發Orpathys（savolitinib）
提起訴訟 → Merck與AstraZeneca挑戰Medicare藥價協商制度之訴訟相繼遭聯邦法院駁回2026-08-19強確認Merck, AZ lawsuits against Medicare price negotiations swatted downAstraZeneca對CMS藥物分組計算方式提起訴訟，遭馬里蘭州聯邦地區法院駁回
發布 → AstraZeneca／Amgen Tezspire（tezepelumab）CROSSING第三期試驗於嗜酸性食道炎達主要終點2026-08-27強確認Tezspire CROSSING Phase III trial met primary endpoints in eosinophilic oesophagitis公布Tezspire CROSSING第三期試驗於嗜酸性食道炎達主要終點
發布 → AstraZeneca／Ionis之Wainua（eplontersen）ATTR-CM三期CARDIO-TTRansform試驗未達主要終點，ESC年會發表完整數據2026-08-29強確認Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathyAstraZeneca於ESC年會發表Wainua ATTR-CM試驗完整數據

更新紀錄

日期變更內容依據來源
2026-07-15首次建檔：以最高15億美元授權取得迪哲醫藥Zegfrovy全球權利AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical
2026-07-24補充：乳癌新藥camizestrant（Etcamah）獲歐盟核准，惟FDA對同一適應症延後裁決，形成歐美監管標準分歧Camizestrant recommended for breast cancer in EU (Etcamah approved in the EU for ER+ breast cancer)
2026-08-03補充：傳出與Bristol Myers Squibb近4000億美元合併早期談判，未經雙方證實，股價一度重挫逾7%AstraZeneca said to have explored Bristol Myers merger
2026-08-07補充：與石藥集團（CSPC）於中國河北石家莊成立生物製劑原料藥製造合資企業（AstraZeneca佔49%），為雙方三年內第三次重大戰略協議CSPC Pharmaceutical, AstraZeneca Form Joint Venture for New Biologics Manufacturing Facility in China
2026-08-18補充：肺癌管線一日三案——volrustomig第三期試驗因無效終止；Enhertu（與第一三共合作）於一線HER2突變NSCLC達標；Orpathys併Tagrisso（與HUTCHMED合作）於EGFR突變NSCLC達標AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure
2026-08-30補充：與Amgen共同開發之Tezspire（tezepelumab）CROSSING第三期試驗於嗜酸性食道炎達主要終點Tezspire CROSSING Phase III trial met primary endpoints in eosinophilic oesophagitis
2026-08-31補充：與Ionis共同開發之Wainua（eplontersen）ATTR-CM三期CARDIO-TTRansform試驗未達主要終點，完整數據於ESC年會發表Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy
2026-09-05補充：美國FDA已於9/4對camizestrant（Etcamah）一線乳癌適應症核予加速核准FDA Grants Accelerated Approval for New Breast Cancer Treatment (camizestrant/Etcamah)

來源

標題發布日期來源機構分級可信度
AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical2026-07-14AstraZeneca（公司新聞稿）第一級高
Camizestrant recommended for breast cancer in EU (Etcamah approved in the EU for ER+ breast cancer)2026-07-23AstraZeneca（公司新聞稿）第一級高
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm2026-07-23FiercePharma第二級高
AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed'2026-08-03CNBC第二級中（原文WebFetch回應403，本則依搜尋引擎摘要與標題轉述）
AstraZeneca said to have explored Bristol Myers merger2026-08-02Fortune（轉述Bloomberg報導）第二級高
Editor's Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea2026-08-03FiercePharma第二級高
CSPC Pharmaceutical, AstraZeneca Form Joint Venture for New Biologics Manufacturing Facility in China2026-08-05PharmExec第二級高
AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure2026-08-17FiercePharma第二級高
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer2026-08-17BioPharma Dive第二級高
Tezspire CROSSING Phase III trial met primary endpoints in eosinophilic oesophagitis2026-08-27AstraZeneca第一級高
Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy2026-07-09AstraZeneca（官方媒體中心）第一級高（AstraZeneca官方公告，完整數據於2026年8月歐洲心臟學會（ESC）年會發表，另交叉核對STAT News、pharmaphorum報導）
FDA Grants Accelerated Approval for New Breast Cancer Treatment (camizestrant/Etcamah)2026-09-04U.S. Food and Drug Administration第一級高
AZ's Baxfendy not worth its price tag, ICER says2026-08-13FiercePharma第二級高